Using positron emission tomography to facilitate CNS drug development

To link to full-text access for this article, visit this link: http://dx.doi.org/10.1016/j.tips.2006.04.004 Byline: Chi-Ming Lee (a), Lars Farde (b) Abstract: Positron emission tomography (PET) is a non-invasive technology of nuclear medicine that has sensitivity for tracing low picomolar concentrations of radiolabeled molecules in the human body. Radiolabeling a new drug to high specific radioactivity facilitates a detailed mapping of its distribution to crucial organs in humans after the administration of a 'microdose' ( Author Affiliation: (a) AstraZeneca Pharmaceuticals, 1800 Concord Pike, Wilmington, DE 19850, USA (b) AstraZeneca R&D Sodertalje, SE-15185, Sodertalje, Sweden, and Department of Clinical Neuroscience, Karolinska Institutet, SE-17176 Stockholm, Sweden